Study #2022-0372
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment
MD Anderson Study Status
Enrolling
Treatment Agent
EG-70 (phase 1), EG-70 (phase 2)
Description
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Study phase:
Physician name:
Ashish Kamat
Department:
Urology
For general questions about clinical trials:
1-855-532-0775
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.